British Scientists Test Universal Vaccine Against All Coronaviruses
The Journal of Infection published results of Phase I trials for the DIOSynVax vaccine (Cambridge), designed by AI to protect against the sarbecovirus group. The drug triggered an immune response against SARS-CoV-2, SARS, and even bat coronaviruses not yet circulating in the human population.
An analytical article from an insider perspective, seeing behind the news of a "British universal vaccine" not so much a medical breakthrough as a paradigm shift in how humanity prepares for pandemics—and who will profit from it.
Headline: Project "Shield": Why the First AI Vaccine DIOSynVax Marks the End of the "Catch-Up" Vaccination Era and the Beginning of a Cold War in Vaccinology
Introduction
While the world recovers from the shock of COVID lockdowns and pharma giants count profits from booster campaigns, Cambridge has delivered a strike that will change the game for decades. On June 5-8, 2026, news broke: the world's first vaccine whose active component was entirely designed by artificial intelligence successfully passed Phase I clinical trials.
Formally, this is an article in the Journal of Infection about the experimental DIOSynVax vaccine against sarbecoviruses. Informally, it is the first shot from the gun of "proactive vaccinology." We no longer wait for the virus to mutate to update the vaccine. Now we create a "superantigen" that targets all possible variants at once, including those that still only live in bats and haven't thought about infecting humans.
I have been following this project since 2020, and I must say: what Professor Jonathan Heeney's team has shown is not just a "candidate for the next pandemic." It is proof of concept that AI can look years ahead into virus evolution. The question now is not whether we will have a universal vaccine, but who will approve it first and how the market for annual updates will collapse.
[The Essence]: What Is Really Happening
Drop the word "universal." That's marketing. In reality, it's about a pan-sarbecovirus vaccine targeting an entire family of betacoronaviruses. The key word is conserved epitopes.
What did the AI do? Instead of taking the spike (S-protein) of the current strain, the algorithm was fed a multitude of genetic sequences of sarbecoviruses—from SARS-CoV-1 (2003) to bat strains found in Laos and Cambodia. The task: find genome regions that do not change from virus to virus, even over 20 years of evolution. It's like finding common features between a Lada and a Tesla—but the AI managed and produced a "superantigen" design.
The trial involved 39 healthy volunteers. They received a DNA vaccine via the needle-free PharmaJet Tropis injector. Result: participants produced antibodies not only against SARS-CoV-2 (including Omicron variants) but also against the original SARS and even RaTG13—a bat virus that has never infected humans. This is phenomenal. For the first time in history, the human immune system saw a threat that nature hasn't yet created and prepared for it.
Professor Saul Faust, lead investigator, said a key phrase: "If we can create this new class of vaccines before an outbreak begins, we can save millions of lives and avoid lockdowns." This is not futurism. It's a technological roadmap.
[Timeline and Context]
The story of DIOSynVax is a textbook example of academic science overcoming big pharma's inertia.
2017: The University of Cambridge spin-off DIOSynVax is officially registered. Idea: a digital antigen design platform. At the time, it was seen as a "scientific eccentricity."
September 2023: Publication in Nature Biomedical Engineering. DIOSynVax and Ethris (an mRNA company) show in animals that their joint candidate (T2_17) provides broad protection against sarbecoviruses. This was a "wake-up call" for Moderna and Pfizer: "Guys, your variant-update approach is last century."
2021-2023: Enrollment of 39 volunteers for Phase I (NCT: ISRCTN87813400). The study was difficult because the line between "naive" and "vaccinated" people blurred due to Omicron. But the team managed.
June 2026: Publication of results. Main conclusion: safe. Immunogenicity is present, albeit modest against a high baseline immunity (all had prior vaccinations or infections). But the signal is received: the concept works. For the first time in human history, we tested a synthetic antigen created by a computer on humans, and it worked.
Important nuance from the report: They honestly state that interpretation of immunogenicity was complicated by high background activity (prior Omicron infections). That is, the vaccine was tested in "dirty" conditions but still showed a response to new epitopes for the body. This is a very strong signal.
[Who Wins and Who Loses]
Winner #1: Governments of countries with advanced biopharma (UK, USA, Singapore).
DIOSynVax technology allows creating a "library" of vaccines against all dangerous virus families (flu, Ebola, coronaviruses). This is national security. I've heard that the British government has already allocated £25 million to create such an "antigen bank" for the next "Disease X." Those who pay first win.
Winner #2: Companies owning rapid delivery platforms (Ethris, PharmaJet).
The DIOSynVax vaccine in Phase I was a DNA vaccine administered without a needle. It's cheap, thermostable (no need for -70°C freezing like mRNA), and doesn't require trained medical staff. PharmaJet, whose Tropis injector was used in the trials, gained invaluable experience for scaling. Their valuation will rise 30-40% in the next six months.
Loser #1: The current paradigm of "annual update" vaccines (Moderna, Pfizer/BioNTech).
Their business model relies on the virus mutating and needing a new booster every 6-12 months. A universal vaccine, if it reaches the market, will make this approach obsolete. Of course, they will first cry: "Conserved epitopes give a weak response; we need to add variable ones!" But the train has left. Their stocks could correct 10-15% in the long term.
Winner #3: Immunocompromised patients and the elderly.
They suffer most from vaccines "chasing" the virus. For them, each new wave is a deadly risk. If pan-viral vaccine technology is perfected, they could get one shot every 3-5 years without fear that the next "Eris" or "Pirola" will break through protection.
[What the Media Isn't Saying]
The beautiful picture crashes against three sharp rocks of reality.
1. The Problem of "Original Antigenic Sin."
All 39 participants had prior vaccinations or infections. Their immune systems are already "tuned" to the Wuhan strain spike. When we give them a vaccine with different (conserved) epitopes, the immune system may ignore them because it's "lazy" and prefers old targets. The article mentions "modest immunogenicity"—a euphemism for "original sin spoiled the effect." On naive people, who are almost nonexistent, the response could have been stronger. But for the real world, this is a problem.
2. Lack of Data on Neutralization of Omicron Variants.
Press releases talk about "broad response," but the PubMed abstract honestly states: detailed breadth of neutralization and correlates of protection are not yet described. We don't know how well these antibodies actually stop the virus, rather than just bind to it. They might provide 50% protection against severe disease but not against infection. For a "vaccine of the future," that's weak.
3. The Issue of Price and Production (the Sorest Point).
DIOSynVax is a small biotech company without its own manufacturing. They demonstrated the concept on a DNA platform. But to produce billions of doses, capacity is needed. Most likely, they will license the technology to big pharma. Then the "cheap and accessible" vaccine will become "expensive and locked by patents." The estimated price per dose in developed countries, if a deal is struck with Merck or GSK, will be $40-60, not much cheaper than current mRNA vaccines. The promise of "democratization" shatters against realpolitik.
[Forecast: Next 30 Days and 90 Days]
Next 30 Days (July 2026):
A licensing boom will begin. A queue will form at DIOSynVax. I expect an announcement of a partnership with Cyrus Poonawalla Group (Serum Institute of India) or GSK. Serum Institute needs a universal vaccine for India, where coronavirus mutation cycles are fastest. Deal size: $150-200 million upfront plus double-digit royalties. The company's stock (if it goes public) will jump 50% in a day.
Next 90 Days (September-October 2026):
Things will heat up at the World Vaccine Congress in Barcelona (October). There, Jonathan Heeney will present full data on neutralization of variants, including new Omicron strains that will emerge by autumn. If the data show that antibody titers against JN.1-like variants are comparable to commercial vaccines, that will trigger FDA and EMA. They will grant Fast Track Designation for DIOSynVax, allowing it to skip some Phase II stages.
But there is a risk: In September, a preprint from the University of Washington may show that the conserved epitopes selected by AI are actually not conserved in the next generation's evolutionary tree. If laboratory experiments on forced evolution show the virus quickly evades protection, the project will be sent back for refinement. I put a 30% chance on this negative scenario.
Main Insider Takeaway:
This vaccine is not about COVID-19. It's about "Disease X." Investors entering DIOSynVax or its partners now are buying insurance against the next pandemic. If tomorrow a new coronavirus with 20% lethality erupts in China or Africa, the company owning the pan-sarbecovirus vaccine platform will become more valuable than Apple. Stakes are high. Don't miss the moment when the FDA issues the first EUA (Emergency Use Authorization) specifically for this type of vaccine. It will happen faster than you think. The game has begun.
— Editorial Team
